Investment in HPV biomarker immunoassay
Investors in biotech innovator Abviris Deutschland are injecting almost two million Euros to speed up expansion, after promising results for its immunoassay biomarker for the early diagnosis of cancers caused by human papillomavirus (HPV).
The Abviris biomarker incorporated into its CE-marked Prevo-Check point-of-care (POC) system focuses on HPV16, the most aggressive of all HPV strains and responsible for more than 90% of all HPV-related head and neck tumours, and for over half of cervical cancer cases. It relies on detecting an immune response that only occurs when HPV infection has triggered tumour growth. This is the first available blood-based test shown to be specific enough to aid in diagnosis
The company is already spearheading the development of further POC applications for the immunoassay technology, designed to address the clinical needs of other high-risk HPV types. Dr. Roman Niedbal, the company’s new CEO, explained: “Abviris is on the cusp of major expansion, with this pivotal study drawing immediate attention from potential partners and clinicians keen to collaborate.
Other News
Featured Supplier
For over 40 years Alpha Laboratories has been providing quality supply and support to UK healthcare professionals for their diagnostic and laboratory product needs. With a continued drive to find new ways to help science improve people’s lives, it focuses on specialist biomarkers such as calprotectin for IBD, alongside routine...
Upcoming Events
Every Minute Counts: a SHOT, BBTS and NBTC joint webinar
Online
3 December 2021
IBMS Biomedical Science Congress 2022
International Convention Centre, Birmingham
14-17 March 2022
Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.
Download the FREE Pathology In Practice app from your device's App store
